Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1171484 | 0.84 | CNR1 (0.37) | PTGS2TUBB1 | |
| SCHEMBL7690729 | 0.82 | NQO1 (0.34) | PTGS2TRPA1CYP1A2CYP2A6NOS3 | |
| SCHEMBL3367670 | 0.82 | LOXL2 (0.43) | — | |
| SCHEMBL359220 | 0.82 | MAPT (0.38) | — | |
| SCHEMBL1012044 | 0.81 | SKP2 (0.40) | PTGS2TUBB1 | |
| SCHEMBL27876071 | 0.80 | TUBB1 (0.38) | PTGS2TUBB1 | |
| SCHEMBL3363967 | 0.79 | KDM4E (0.50) | CYP1A2TP53 | |
| SCHEMBL931853 | 0.79 | ALOX15 (0.39) | PTGS2TRPA1CYP1A2TP53 | |
| SCHEMBL15353293 | 0.79 | TRPA1 (0.31) | PTGS2TRPA1CYP1A2CYP2A6 | |
| SCHEMBL11212743 | 0.78 | PPARG (0.46) | PTGS2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041212-A | Preparation and application of difluoro olefin ether and oxime ether derivatives | 安徽农业大学 | 2023-05-02 | — | — | CN | claimed |
| CN-113443965-B | Method for generating aryl phenol compound by hydrolyzing diaryl ether compound | 华东师范大学 | 2022-09-20 | — | — | CN | claimed |
| CN-113443965-A | Method for generating aryl phenol compound by hydrolyzing diaryl ether compound | 华东师范大学 | 2021-09-28 | — | — | CN | claimed |
| EP-2170864-B1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2252594-A2 | 5-FLUORO PYRIMIDINE DERIVATIVES AS FUNGICIDES | Dow AgroSciences LLC (US) | 2010-11-24 | — | — | EP | claimed |
| WO-2009131692-A1 | SUBSTRATES FOR DELIVERY OF PHYSIOLOGICALLY ACTIVE AGENTS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009094442-A2 | 5-FLUORO PYRIMIDINE DERIVATIVES | DOW AGROSCIENCES LLC (US) | 2009-07-30 | — | — | WO | claimed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | claimed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | claimed |
| US-4567197-A | THORMBOXANE A2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-28 | — | — | US | claimed |
| CN-113443965-B | Method for generating aryl phenol compound by hydrolyzing diaryl ether compound | 华东师范大学 | 2022-09-20 | — | — | CN | disclosed |
| CN-113443965-A | Method for generating aryl phenol compound by hydrolyzing diaryl ether compound | 华东师范大学 | 2021-09-28 | — | — | CN | disclosed |
| EP-2841429-B1 | TETRAZOLINONE COMPOUNDS AND ITS USE AS PESTICIDES | SUMITOMO CHEMICAL CO (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-4048160-A | Process for preparation of 7-alkoxy-3-bromomethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4048163-A | Process for preparation of 7-alkoxy-3-chloromethylcephems | ELI LILLY AND COMPANY (US) | 1977-09-13 | — | — | US | disclosed |
| US-4042585-A | Process for preparation of 3-halomethylcephems | ELI LILLY AND COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
| US-4038275-A | PROCESS FOR PREPARATION OF 3-HYDROXYMETHYLCEPHEMS | ELI LILLY AND COMPANY (US) | 1977-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | PTGS2 2410/4885TUBB1 3879/4885TRPA1 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.